The SCID-hu myeloma model
- PMID: 15968103
- DOI: 10.1385/1-59259-916-8:183
The SCID-hu myeloma model
Abstract
The severe combined immune deficient human (SCID-hu) myeloma model is the only available model in which primary myeloma cells grow in vivo in a human bone marrow micro environment. A SCID mouse receives an implanted human fetal bone into which myeloma cells are directly injected. Through interaction with the human bone marrow microenvironment, the myeloma cells induce typical myeloma manifestations in the SCID host, such as the appearance of M protein in the serum, and changes in the implanted human bone, which often result in osteolysis of the human bone. The model provides the only platform for in vivo investigation of the biology and therapy of primary human myeloma in a human microenvironment. This chapter describes in detail all the steps necessary to establish this model and evaluate its success.
Similar articles
-
The use of animal models in multiple myeloma.Morphologie. 2015 Jun;99(325):63-72. doi: 10.1016/j.morpho.2015.01.003. Epub 2015 Apr 17. Morphologie. 2015. PMID: 25898798 Review.
-
Combination therapy with interleukin-6 receptor superantagonist Sant7 and dexamethasone induces antitumor effects in a novel SCID-hu In vivo model of human multiple myeloma.Clin Cancer Res. 2005 Jun 1;11(11):4251-8. doi: 10.1158/1078-0432.CCR-04-2611. Clin Cancer Res. 2005. PMID: 15930364
-
Interleukin-18 inhibits lodging and subsequent growth of human multiple myeloma cells in the bone marrow.Oncol Rep. 2002 Nov-Dec;9(6):1237-44. Oncol Rep. 2002. PMID: 12375027
-
Disseminated growth of a human multiple myeloma cell line in mice with severe combined immunodeficiency disease.Cancer Res. 1993 Mar 15;53(6):1392-6. Cancer Res. 1993. PMID: 8443818
-
The SCID-hu mouse: a small animal model for the analysis of human hematolymphoid differentiation and function.Bone Marrow Transplant. 1992;9 Suppl 1:74-6. Bone Marrow Transplant. 1992. PMID: 1354528 Review. No abstract available.
Cited by
-
Laboratory Mice - A Driving Force in Immunopathology and Immunotherapy Studies of Human Multiple Myeloma.Front Immunol. 2021 Jun 2;12:667054. doi: 10.3389/fimmu.2021.667054. eCollection 2021. Front Immunol. 2021. PMID: 34149703 Free PMC article. Review.
-
Bone-targeted agents in multiple myeloma.Hematol Rep. 2018 Mar 29;10(1):7401. doi: 10.4081/hr.2018.7401. eCollection 2018 Mar 2. Hematol Rep. 2018. PMID: 29721251 Free PMC article.
-
Whole Genome Sequence of Multiple Myeloma-Prone C57BL/KaLwRij Mouse Strain Suggests the Origin of Disease Involves Multiple Cell Types.PLoS One. 2015 May 28;10(5):e0127828. doi: 10.1371/journal.pone.0127828. eCollection 2015. PLoS One. 2015. PMID: 26020268 Free PMC article.
-
NOD/SCID-GAMMA mice are an ideal strain to assess the efficacy of therapeutic agents used in the treatment of myeloma bone disease.PLoS One. 2015 Mar 13;10(3):e0119546. doi: 10.1371/journal.pone.0119546. eCollection 2015. PLoS One. 2015. PMID: 25768011 Free PMC article.
-
β-catenin is dynamically stored and cleared in multiple myeloma by the proteasome-aggresome-autophagosome-lysosome pathway.Leukemia. 2012 May;26(5):1116-9. doi: 10.1038/leu.2011.303. Epub 2011 Nov 4. Leukemia. 2012. PMID: 22051532 Free PMC article. No abstract available.
MeSH terms
LinkOut - more resources
Other Literature Sources
Medical